Small Cell Lung Cancer
Conditions
Brief summary
Evaluate the activity and safety of Nab-paclitaxel in patients with sensitive or refractory SCLC who relapsed after cisplatin or carboplatin and etoposide first-line chemotherapy.
Detailed description
Phase II study of NAB-paclitaxel in SensiTivE and Refractory relapsed SCLC
Interventions
DRUGNabpaclitaxel
Chemotherapy will be continued until a maximum of 6 courses or progressive disease or intolerable toxicity or patient refusal. In patients with confirmed and prolonged disease response, clinical benefit and good tolerance to study drug treatment, the investigators can evaluate to continue therapy beyond 6th cycle, after discussion with Principal Investigator (PI) of the study
Sponsors
Temas srl
Clirest s.r.l.
Mipharm S.p.A.
Istituto Toscano Tumori
Gruppo Oncologico Italiano di Ricerca Clinica
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Intervention model description
Open label, multicentre, study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathologically (histology or cytology) confirmed diagnosis of small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC) or poorly differentiated (G3) neuroendocrine cancer of the lung (according to WHO classification 2015) * Male or female and ≥ 18 years of age * Life expectancy ≥ 12 weeks * Have progressed after or during platinum-based standard chemotherapy regimen (cisplatin or carboplatin and etoposide) for first-line treatment of SCLC, either limited stage (LD) or extensive stage (ED) disease and have not received any other treatment (except for immunotherapy as maintenance treatment), including re-treatment with front-line regimen * Have measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1); clear radiological evidence of disease progression after first-line therapy has to be documented; no previous radiotherapy on the only site of measurable or evaluable disease, unless that site had subsequent evidence of progression * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 * Patients with treated brain metastases with stable lesions for at least 2 weeks and off steroids or on a stable dose of steroids. Radiotherapy must have been completed a minimum of 14 days prior to registration, and patients must have recovered from AEs related to radiotherapy to \< grade 1 (except alopecia) * For Females: must be postmenopausal (defined as occurring 12 months after last menstrual period) before the screening visit, or are surgically sterile. If they are of childbearing potential, a negative serum pregnancy test prior to study entry has to be documented; furthermore, they agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form (ICF) through 30 days after the last dose of study drug, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject * For Males: even if surgically sterilized (i.e. post-vasectomy status) agree to practice effective barrier contraception during the entire study treatment period and through 6 months after the last dose of study drug, or practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject * Screening clinical laboratory values as specified below: * Absolute neutrophil count (ANC) ≥ 1500/mm3, platelet count ≥ 100,000/mm3 and haemoglobin ≥ 9 g/dL * Total bilirubin \< 1.5 the institutional upper limit of normal (ULN) * Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 2.5 the institutional ULN (\< 5 if liver function test elevations are due to liver metastases) * Creatinine \< 1.5 institutional ULN or estimated creatinine clearance using the Cockcroft-Gault formula ≥ 30 mL/minute for patients with creatinine levels above institutional limits * Stable medical condition, including the absence of acute exacerbations of chronic illnesses, serious infections, or major surgery within 4 weeks before registration, and otherwise noted in other inclusion/
Exclusion criteria
* Recovered (i.e., ≤ Grade 1 toxicity) from effects of prior anticancer therapy, except alopecia * Prior radiotherapy is allowed provided that it has been completed more than 2 weeks before starting Nab-paclitaxel * Ability to comply with protocol requirements * The patient or the patient's legal representative has to be able to provide written informed consent. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary end-point is objective tumor response | From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 weeks. | It will be evaluated according to standard RECIST 1.1 criteria and will be based on the Investigator's assessment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of Toxicity Events: frequency of moderate and severe toxicity events and drop-out rate due to therapy related toxicity | From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 weeks. | The assessment of safety will be based mainly on the frequency of adverse events. Adverse events will be summarized by presenting the number and percentage of patients having any adverse event, having an adverse event in each body system and having each individual adverse event. Toxicity descriptive tables will be produced which provide the worst degree of toxicity measured over all cycles according to the CTCAE version 4.03 |
| Progression Free Survival (PFS) | From date of registration until the date of last documented progression or date of death from any cause, assessed up to 100 weeks | will be calculated from the patient registration to the evidence of progressive disease, or death, or the last date the patient was known to be progression-free or alive. |
| Overall Survival (OS) | From date of patient enrolment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | will be calculated from the registration to death from any cause, or the last date the patient was known to be alive from the registration to death from any cause, or the last date the patient was known to be alive |
Countries
Italy
Contacts
Primary ContactGOIRC
Backup ContactAndrea Ardizzoni, PI
Outcome results
None listed